scispace - formally typeset
S

Shih Shin Chang

Researcher at University of Texas MD Anderson Cancer Center

Publications -  32
Citations -  4368

Shih Shin Chang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Lytic cycle. The author has an hindex of 24, co-authored 32 publications receiving 3011 citations. Previous affiliations of Shih Shin Chang include University of Texas Health Science Center at Houston & University of Texas at Austin.

Papers
More filters
Journal ArticleDOI

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Chia Wei Li, +26 more
- 30 Aug 2016 - 
TL;DR: The results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.
Journal ArticleDOI

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Shiping Jiao, +22 more
- 15 Jul 2017 - 
TL;DR: A cross-talk between PARPi and tumor-associated immunosuppression is demonstrated and evidence is provided to support the combination of PAR Pi and PD-L1 or PD-1 immune checkpoint blockade as a potential therapeutic approach to treat breast cancer.
Journal ArticleDOI

Deubiquitination and Stabilization of PD-L1 by CSN5

Seung Oe Lim, +23 more
- 12 Dec 2016 - 
TL;DR: It is demonstrated that COP9 signalosome 5 (CSN5), induced by NF-κB p65, is required for TNF-α-mediated PD-L1 stabilization in cancer cells, and inhibition of CSN5 by curcumin diminished cancer cell PD- L1 expression and sensitized cancer cells to anti-CTLA4 therapy.
Journal ArticleDOI

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

Jong Ho Cha, +27 more
- 16 Aug 2018 - 
TL;DR: It is shown that metformin increases CTL activity by reducing the stability and membrane localization of programmed death ligand-1 (PD-L1), and it is discovered that AMP-activated protein kinase (AMPK) activated by met formin directly phosphorylates S195 of PD-L 1.
Journal ArticleDOI

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

Chia Wei Li, +27 more
- 12 Feb 2018 - 
TL;DR: Targeting protein glycosylation as a potential strategy to enhance immune checkpoint therapy is suggested, as it remains largely unknown whether the sugar moiety contributes to immunosuppression.